Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
Aymanjed / Pixabay

Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug

According to a press release from Alnylam Pharmaceuticals, the Massachusetts-based biopharmaceutical company has completed the submission of its New Drug Application (NDA) for givosiran — its experimental acute hepatic porphyria…

Continue Reading Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
4 out of 5 Functional Neurological Disorder Patients Have Lasting Neurological Symptoms
source: pixabay.com

4 out of 5 Functional Neurological Disorder Patients Have Lasting Neurological Symptoms

  Functional neurological disorder is a conversion disorder. This type of complex disorder is often thought to be linked with psychological symptoms, serious stress, or mental distress. With functional neurological…

Continue Reading 4 out of 5 Functional Neurological Disorder Patients Have Lasting Neurological Symptoms
New Discoveries Reveal Further Connections Between the Gut Microbiome, Human Health, and Rare Diseases
geralt / Pixabay

New Discoveries Reveal Further Connections Between the Gut Microbiome, Human Health, and Rare Diseases

According to a story from bioengineer.org, a team of researchers associated with Oregon State University are making further headway in understanding the connection between our health and the bacteria that…

Continue Reading New Discoveries Reveal Further Connections Between the Gut Microbiome, Human Health, and Rare Diseases
First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease
Free-Photos / Pixabay

First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease

Do you have ADPKD? If you or someone you know has ADPKD, email us at Contribute@patientworthy.com. We'd love to hear from you about your experience! According to a story from…

Continue Reading First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease

The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

  In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…

Continue Reading The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals